{"path":"Zotero Images/image-3-x56-y437.png","text":"Table 2 Management of DCM Medical management Angiotensin-converting ® Inhibit rennin-angiotensin- enzyme inhibitors aldosterone system (ACE-I) * Improve dyspnoea and exercise tolerance * Reduce hospital stay ¢ Slow disease progression ¢ Reduce mortality Angiotensin Il receptor ® Useful if patients cannot tolerate inhibitors (A-II) ACE-I ¢ Little benefit if used with ACE-I Beta-blockers ¢ Reduce mortality in heart failure Aldosterone inhibitors: ® Reduce mortality in heart failure spironolactone and * Eplerenone does not cause eplerenone gynaecomastia Atrial natriuretic * Causes diuresis, natriuresis, and peptides vasodilation ¢ Administered via i.v. route only Anticoagulants ¢ Indicated in the presence of systolic dysfunction (ejection fraction <30%) Non-medical manage- ® Partial left ventriculectomy ment of advanced ¢ Left ventricle assist devices heart failure ¢ Multi-site ventricular pacing * ICDs * Heart transplantation","libVersion":"0.3.2","langs":"eng"}